87 related articles for article (PubMed ID: 3352757)
1. Administration of radiation or cyclophosphamide versus alternated radiation and cyclophosphamide treatment of primary tumor and pulmonary metastases.
Looney WB; Hopkins HA
NCI Monogr; 1988; (6):145-6. PubMed ID: 3352757
[TBL] [Abstract][Full Text] [Related]
2. Comparison of effects of daily versus hyperfractionated split-course radiation schedules with and without cyclophosphamide on median survival, metastatic dissemination, tumor cure, and growth rates.
Looney WB; Hopkins HA; Longerbeam MB; Carter WH
Cancer Res; 1983 Jan; 43(1):60-7. PubMed ID: 6847784
[TBL] [Abstract][Full Text] [Related]
3. Relationship of tumor regrowth to tumor cell survival, tumor cure rates and host survival in a solid tumor model following combined chemotherapy and radiotherapy.
Hopkins HA; Looney WB; Carter WH; Reto DC; Campbell ED
In Vivo; 1994; 8(1):97-105. PubMed ID: 8054518
[TBL] [Abstract][Full Text] [Related]
4. Multiple drug chemotherapy combined with multiple fractions per day (MFD) radiotherapy in an experimental solid tumor model.
Hopkins HA; Looney WB; Carter WH; Reto DC; Campbell ED
In Vivo; 1994; 8(1):107-12. PubMed ID: 8054501
[TBL] [Abstract][Full Text] [Related]
5. Solid tumor models for the assessment of different treatment modalities: XXIII. A new approach to the more effective utilization of radiotherapy alternated with chemotherapy.
Looney WB; Hopkins HA; Carter WH
Int J Radiat Oncol Biol Phys; 1985 Dec; 11(12):2105-17. PubMed ID: 4066443
[TBL] [Abstract][Full Text] [Related]
6. Solid tumor models for the assessment of different treatment modalities. XXII. The alternate utilization of radiotherapy and chemotherapy.
Looney WB; Hopkins HA; Carter WH
Cancer; 1984 Aug; 54(3):416-25. PubMed ID: 6733674
[TBL] [Abstract][Full Text] [Related]
7. Solid tumor models for the assessment of different treatment modalities. XXI. Comparison of different radiation dose schedules alone or in combination with cyclophosphamide.
Looney WB; Longerbeam MB; Hopkins HA; Carter WH
Cancer; 1983 Mar; 51(6):1012-20. PubMed ID: 6821865
[TBL] [Abstract][Full Text] [Related]
8. Survival of mice with metastatic osteosarcoma treated by cyclophosphamide or radiotherapy.
Shaeffer J; El-Mahdi AM; Constable WC
Cancer Res; 1975 Dec; 35(12):3596-8. PubMed ID: 1059504
[TBL] [Abstract][Full Text] [Related]
9. Lewis lung carcinoma in mice as an experimental therapy model. II. The effect of BCNU, cyclophosphamide and/or surgery treatment on early and advanced tumor in mice.
Budzyński W
Arch Immunol Ther Exp (Warsz); 1982; 30(5-6):373-7. PubMed ID: 7184488
[TBL] [Abstract][Full Text] [Related]
10. Enhancement by cyclophosphamide of experimental pulmonary metastases formation of Lewis lung carcinoma. I. Dose-dependence and kinetics of cyclophosphamide effect.
Strzadała L; Rak J; Kuśnierczyk H
Arch Immunol Ther Exp (Warsz); 1985; 33(6):825-9. PubMed ID: 3833119
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary metastases of the lewis lung tumor-cell kinetics and response to cyclophosphamide at different sizes.
Hill RP; Stanley JA
Cancer Treat Rep; 1977; 61(1):29-36. PubMed ID: 861961
[TBL] [Abstract][Full Text] [Related]
12. Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin.
Gautam A; Waldrep JC; Densmore CL; Koshkina N; Melton S; Roberts L; Gilbert B; Knight V
Gene Ther; 2002 Mar; 9(5):353-7. PubMed ID: 11938455
[TBL] [Abstract][Full Text] [Related]
13. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
Teicher BA; Ara G; Buxton D; Leonard J; Schaub RG
Clin Cancer Res; 1997 Sep; 3(9):1661-7. PubMed ID: 9815857
[TBL] [Abstract][Full Text] [Related]
14. Effect of sequence of combined radiation and cyclophosphamide regimens on murine osteosarcoma.
El-Mahdi AM; Shaeffer J
Cancer Treat Rep; 1977 Nov; 61(8):1569-71. PubMed ID: 270390
[No Abstract] [Full Text] [Related]
15. Radiation therapy to a primary tumor accelerates metastatic growth in mice.
Camphausen K; Moses MA; Beecken WD; Khan MK; Folkman J; O'Reilly MS
Cancer Res; 2001 Mar; 61(5):2207-11. PubMed ID: 11280788
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin/etoposide chemotherapy combined with twice daily thoracic radiotherapy for limited small-cell lung cancer: a clinical phase II trial.
Chen GY; Jiang GL; Wang LJ; Qian H; Fu XL; Yang H; Wu KL; Zhao S
Int J Radiat Oncol Biol Phys; 2005 Jan; 61(1):70-5. PubMed ID: 15629596
[TBL] [Abstract][Full Text] [Related]
17. Solid tumor models for the assessment of different treatment modalities: XVI. Sequential combined modality (Cyclophosphamide-Radiation) therapy.
Looney WB; Ritenour ER; Hopkins HA
Cancer; 1981 Mar; 47(5):860-9. PubMed ID: 7226039
[TBL] [Abstract][Full Text] [Related]
18. Combination chemotherapy and IL-15 administration induce permanent tumor regression in a mouse lung tumor model: NK and T cell-mediated effects antagonized by B cells.
Chapoval AI; Fuller JA; Kremlev SG; Kamdar SJ; Evans R
J Immunol; 1998 Dec; 161(12):6977-84. PubMed ID: 9862733
[TBL] [Abstract][Full Text] [Related]
19. Radiation therapy enhances the therapeutic effect of immunotherapy on pulmonary metastases in a murine renal adenocarcinoma model.
Chakrabarty A; Hillman GG; Maughan RL; Ali E; Pontes JE; Haas GP
In Vivo; 1994; 8(1):25-31. PubMed ID: 8054507
[TBL] [Abstract][Full Text] [Related]
20. Solid tumor models for the assessment of different treatment modalities: XXVI. Estimates of cell survival from tumor growth delay after alternating radiotherapy and chemotherapy.
Hopkins HA; Looney WB
Int J Radiat Oncol Biol Phys; 1987 Feb; 13(2):217-24. PubMed ID: 3818388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
